RCT partners with Isogenica for large-scale screening of CH2 domains
7.11.2012
Research Corporation Technologies, Inc. (RCT), of Tucson, has partnered with Isogenica, of Cambridge, U.K., to access Isogenica’s CIS display platform for the screening of proprietary libraries of a new antigen-binding protein scaffold.
The RCT libraries are part of a biologics discovery platform to identify engineered antibody fragments called ABDURINS™ for development into therapeutic agents. ABDURINS™ retain the desired long half-life of an antibody’s CH2 domain and are engineered for enhanced stability, epitope binding and other properties. To facilitate screening of the novel ABDURINS™ libraries, RCT has partnered with Isogenica to provide interested parties access to their proprietary, high throughput display and screening platform called CIS display. CIS display can screen significantly larger libraries and isolate and optimize lead binders in a fraction of the time it takes using phage display. In addition to CIS display, Isogenica will support RCT through deep sequencing and related bioinformatics tools that can inform the optimisation of the selected ABDURINS™.
“Isogenica’s CIS display offers a significant advantage over other screening systems by allowing for primary screening and binder optimization in one system. The pairing of CIS display with our ABDURINS™ platform will be an attractive offering to potential partners,” stated Dr. Kurt Gehlsen, Vice President and CSO of RCT.
Dr. Kevin Matthews, CEO of Isogenica commented, “Our agreement with RCT underlines the value that CIS display brings to companies that are pioneering new antibody scaffolds for the development of better medicines. We look forward to supporting the deployment of RCT’s ABDURINS™ library and working with their biopharma collaborators to find new therapeutic candidates.”
About Isogenica
Isogenica specialises in the discovery and optimisation of therapeutic and diagnostic peptides, proteins and antibodies using its proprietary technology, CIS display. Founded in 2000, Isogenica has developed a unique capability in the field of protein engineering. Isogenica’s CIS display technology is an in vitro display technology that allows the rapid generation of polypeptide and antibody libraries from which it is possible to select lead molecules with high affinity and specificity for most targets. Isogenica.com.
For further information contact:
Kevin Matthews
CEO, Isogenica
+44 (0)1799 533682
Kevin.Matthews@Isogenica.com
Sarah Brereton
Limewash Media & Design
+44 (0)7796 583 223
Sarah@LimewashMedia.com
About RCT
RCT is a Tucson, Ariz.-based technology investment and management company that provides early-stage funding and development for promising biomedical companies and technologies. RCT focuses on technology investments with origins from universities and research institutions worldwide. RCT’s ABDURINS ™ platform has been developed under collaboration with Dr. Dimitri Dimitrov’s Protein Interactions Group of the National Cancer Institute at the National Institutes of Health. To learn more, see RCTech.com.